-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Imago BioSciences (NASDAQ:IMGO) Trading Down 7%
Imago BioSciences (NASDAQ:IMGO) Trading Down 7%
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) traded down 7% during mid-day trading on Monday . The stock traded as low as $17.04 and last traded at $17.11. 846 shares were traded during trading, a decline of 100% from the average session volume of 204,228 shares. The stock had previously closed at $18.39.
Analyst Upgrades and Downgrades
Separately, HC Wainwright dropped their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Trading Up 5.2 %
The firm has a fifty day simple moving average of $15.66 and a 200-day simple moving average of $17.66.
Insider Activity
In other news, insider Jennifer Peppe sold 5,598 shares of the business's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at approximately $2,888,382.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 7,721 shares of company stock worth $147,356. 14.90% of the stock is currently owned by insiders.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMGO. Allspring Global Investments Holdings LLC acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $94,000. New York State Common Retirement Fund acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $154,000. Northern Trust Corp boosted its position in Imago BioSciences by 25.0% during the 4th quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after purchasing an additional 21,413 shares during the period. Swiss National Bank acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $612,000. Finally, Alps Advisors Inc. acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $920,000. Institutional investors and hedge funds own 88.28% of the company's stock.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
- Are Ocugen or Amarin Good Penny Stocks to Buy?
- Are These 2 Fintechs A Buy After Q2 Earnings?
- Chipotle is Cooking Up Another Run at $2,000
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) traded down 7% during mid-day trading on Monday . The stock traded as low as $17.04 and last traded at $17.11. 846 shares were traded during trading, a decline of 100% from the average session volume of 204,228 shares. The stock had previously closed at $18.39.
周一午盘,Imago BioSciences,Inc.(纳斯达克代码:IMGO-GET Rating)的股价下跌了7%。该股最低交易价格为17.04美元,最后报17.11美元。当日成交量为846股,较204,228股的平均日成交量下降100%。该股此前收盘价为18.39美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, HC Wainwright dropped their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
另外,在8月16日星期二的一份报告中,HC Wainwright将Imago BioSciences的目标价从36.00美元下调至35.00美元,并对该股设定了买入评级。
Imago BioSciences Trading Up 5.2 %
Imago BioSciences股价上涨5.2%
The firm has a fifty day simple moving average of $15.66 and a 200-day simple moving average of $17.66.
该公司的50日简单移动均线为15.66美元,200日简单移动均线为17.66美元。
Insider Activity
内幕活动
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMGO. Allspring Global Investments Holdings LLC acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $94,000. New York State Common Retirement Fund acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $154,000. Northern Trust Corp boosted its position in Imago BioSciences by 25.0% during the 4th quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after purchasing an additional 21,413 shares during the period. Swiss National Bank acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $612,000. Finally, Alps Advisors Inc. acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $920,000. Institutional investors and hedge funds own 88.28% of the company's stock.
一些对冲基金和其他机构投资者最近增持或减持了IMGO的股份。AllSpring Global Investments Holdings LLC在第四季度收购了Imago BioSciences的一个新头寸,价值约为9.4万美元。纽约州共同退休基金在第四季度收购了Imago BioSciences的一个新头寸,价值约为154,000美元。北方信托公司在第四季度将其在Imago BioSciences的地位提高了25.0%。北方信托公司目前持有107,122股该公司股票,价值2,541,000美元,在此期间又购买了21,413股。瑞士国家银行在第四季度收购了Imago BioSciences的一个新头寸,价值约为61.2万美元。最后,Alps Advisors Inc.在第四季度收购了Imago BioSciences的一个新头寸,价值约为92万美元。机构投资者和对冲基金持有该公司88.28%的股票。
About Imago BioSciences
关于Imago BioSciences
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences,Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品,LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat,正在进行第二阶段临床试验,用于治疗骨髓增生性肿瘤和慢性骨髓癌,如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
- Are Ocugen or Amarin Good Penny Stocks to Buy?
- Are These 2 Fintechs A Buy After Q2 Earnings?
- Chipotle is Cooking Up Another Run at $2,000
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 请真正的Palantir站起来好吗?
- 只因为买了一件非常诱人的东西就买了脚锁
- Ocugen或Amarin是值得购买的便士股票吗?
- 这两家金融科技公司是在第二季度盈利后买入的吗?
- Chipotle正在酝酿另一轮2000美元的涨势
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧